TITLE

Telomere Length in Relation to Immunological Parameters in Patients with Renal Cell Carcinoma

AUTHOR(S)
Svenson, Ulrika; Grönlund, Elisabeth; Söderström, Ingegerd; Sitaram, Raviprakash T.; Ljungberg, Börje; Roos, Göran
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Over the last decade, telomere length (TL) has gained attention as a potential biomarker in cancer disease. We previously reported that long blood TL was associated with a poorer outcome in patients with breast cancer and renal cell carcinoma. Based on these findings, we hypothesized that certain immunological components may have an impact on TL dynamics in cancer patients. One aim of the present study was to investigate a possible association between serum cytokines and TL of peripheral blood cells, tumors and corresponding kidney cortex, in patients with clear cell renal cell carcinoma. For this purpose, a multiplex cytokine assay was used. Correlation analysis revealed significant positive correlations between tumor TL and peripheral levels of three cytokines (IL-7, IL-8 and IL-10). In a parallel patient group with various kidney tumors, TL was investigated in whole blood and in immune cell subsets in relation to peripheral levels of regulatory T cells (Tregs). A significant positive association was found between whole blood TL and Treg levels. However, the strongest correlation was found between Tregs and TL of the T lymphocyte fraction. Thus, patients with higher Treg levels displayed longer T cell telomeres, which might reflect a suppressed immune system with fewer cell divisions and hence less telomere shortening. These results are in line with our earlier observation that long blood TL is an unfavorable prognostic factor for cancer-specific survival. In summary, we here show that immunological components are associated with TL in patients with renal cell carcinoma, providing further insight into the field of telomere biology in cancer.
ACCESSION #
87623830

 

Related Articles

  • Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. Alcaraz, A; González-López, R; Morote, J; de la Piedra, C; Meseguer, C; Esteban, E; Climent, M; González-Gragera, B; Álvarez-Ossorio, J-L; Chirivella, I; Mellado, B; Lara, P-C; Vázquez, F; Contreras, J-A; Carles, J; Murias, A; Calderero, V; Comet-Batlle, J; González-del Alba, A; León-Mateos, L // British Journal of Cancer;7/9/2013, Vol. 109 Issue 1, p121 

    Background:Levels of bone turnover markers (BTM) might be correlated with outcome in terms of skeletal-related events (SRE), disease progression, and death in patients with bladder cancer (BC) and renal cell carcinoma (RCC) with bone metastases (BM). We try to evaluate this possible correlation...

  • Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. Ridolfi, Laura; de Rosa, Francesco; Ridolfi, Ruggero; Gentili, Giorgia; Valmorri, Linda; Scarpi, Emanuela; Parisi, Elisabetta; Romeo, Antonino; Guidoboni, Massimo // Journal of Translational Medicine;2014, Vol. 12 Issue 1, p1 

    Background Tumor cells killed by radiation therapy (RT) are a potentially good source of antigens for dendritic cell (DC) uptake and presentation to T-cells. RT upregulates cell death receptors such as Fas/CD95 and MHC-I, induces the expression of co-stimulatory molecules on tumor cells, and...

  • Clinical biomarkers of response in advanced renal cell carcinoma. Ravaud, A.; Schmidinger, M. // Annals of Oncology;Dec2013, Vol. 24 Issue 12, p2935 

    There are now a range of effective targeted agents available for the first- and second-line treatment of advanced renal cell carcinoma (RCC). However, patients with advanced RCC have varied responses to therapy; some experience long-term responses while others may not respond, or even progress...

  • Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Beuselinck, B; Wolter, P; Karadimou, A; Elaidi, R; Dumez, H; Rogiers, A; Van Cann, T; Willems, L; Body, J-J; Berkers, J; Van Poppel, H; Lerut, E; Debruyne, P; Paridaens, R; Schöffski, P // British Journal of Cancer;11/6/2012, Vol. 107 Issue 10, p1665 

    Background:The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without bone involvement. Concomitant bisphosphonates could probably improve outcomes but...

  • Monocyte-derived dendritic cells reflect the immune functional status of a chromophobe renal cell carcinoma patient: Could it be a general phenomenon? Clavijo-Salomon, Maria; Ramos, Rodrigo; Crippa, Alexandre; Pizzo, Celia; Bergami-Santos, Patricia; Barbuto, Jose // Cancer Immunology, Immunotherapy;Feb2015, Vol. 64 Issue 2, p161 

    Purpose: The chromophobe renal cell carcinoma (ChRCC), though associated with a hereditary cancer syndrome, has a good prognosis after tumor removal. The lack of recurrence could be related to the absence of immune system compromise in patients or to an effective functional recovery of immune...

  • Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Guisset, Olivier; Dilhuydy, Marie-Sarah; Thiébaut, Rodolphe; Lefèvre, Jérôme; Camou, Fabrice; Sarrat, Anne; Gabinski, Claude; Moreau, Jean-Fran+ACYAIw-x00E7;ois; Blanco, Patrick; Thiébaut, Rodolphe; Lefèvre, Jérôme; Moreau, Jean-François // Intensive Care Medicine;Jan2007, Vol. 33 Issue 1, p148 

    Objective: Biomarkers allowing accurate early staging of septic shock patients are lacking despite their obvious interest for patient management. Experimental models of septic shock in mouse previously noted a decrease in dendritic cell numbers. The aim of the study was to find a...

  • Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Santegoets, Saskia; Dijkgraaf, Eveline; Battaglia, Alessandra; Beckhove, Philipp; Britten, Cedrik; Gallimore, Awen; Godkin, Andrew; Gouttefangeas, Cecile; Gruijl, Tanja; Koenen, Hans; Scheffold, Alexander; Shevach, Ethan; Staats, Janet; Taskén, Kjetil; Whiteside, Theresa; Kroep, Judith; Welters, Marij; Burg, Sjoerd // Cancer Immunology, Immunotherapy;Oct2015, Vol. 64 Issue 10, p1271 

    Regulatory T cell (Treg)-mediated immunosuppression is considered a major obstacle for successful cancer immunotherapy. The association between clinical outcome and Tregs is being studied extensively in clinical trials, but unfortunately, no consensus has been reached about (a) the markers and...

  • Integration of Lyoplate Based Flow Cytometry and Computational Analysis for Standardized Immunological Biomarker Discovery. Villanova, Federica; Di Meglio, Paola; Inokuma, Margaret; Aghaeepour, Nima; Perucha, Esperanza; Mollon, Jennifer; Nomura, Laurel; Hernandez-Fuentes, Maria; Cope, Andrew; Prevost, A. Toby; Heck, Susanne; Maino, Vernon; Lord, Graham; Brinkman, Ryan R.; Nestle, Frank O. // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Discovery of novel immune biomarkers for monitoring of disease prognosis and response to therapy in immune-mediated inflammatory diseases is an important unmet clinical need. Here, we establish a novel framework for immunological biomarker discovery, comparing a conventional (liquid) flow...

  • Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review. Iuliis, Francesca; Salerno, Gerardo; Taglieri, Ludovica; Scarpa, Susanna; De Iuliis, Francesca // Cancer Chemotherapy & Pharmacology;Oct2015, Vol. 76 Issue 4, p679 

    Purpose: Breast cancer is a heterogeneous disease, characterized by various molecular phenotypes that correlate with different prognosis and response to treatments. Taxanes are some of the most active chemotherapeutic agents for breast cancer; however, their utilization is limited,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics